New in vitro Bioactivation Liver Response Assay used HEPATOPAC model to demonstrate utility of in vitro transcriptomic signature-based strategy in preclinical DILI risk assessment
Westbury, NY – Oct. 12, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the publication of research describing the use of HEPATOPAC® cultures with a targeted in vitro assay to identify small molecule drugs with high potential for drug-induced liver injury (DILI).1